Answers are grounded in this paper and cite their sources.
Despite hugely promising randomized phase II study data, combined CRT plus xevinapant failed in the TrilynX phase III clinical trial in locally advanced SCCHN. We show that adding xevinapant to chemoradiotherapy in vivo dysregulates antitumor lymphocyte function, acute-phase proteins, and cell death pathways, with net immunosuppressive effects on the tumor-immune microenvironment.
No takes yet. Share an insight, caveat, or question.
Hak et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: